Pharma Cos Don’t See Supply Shortage, Oppose Exports Ban
Most industry stakeholders agree that situation will be under control till May
SUDARSHAN JAIN
-
Quality Metrics crucial in manufacturing processes, urge leaders at REPharma Summit 2024
The 4th edition of the REPharma Summit featured an invigorating panel discussion titled “Quality Metrics Transforming Pharma Manufacturing Practices.”
-
REPharma Summit 2024: ‘Reinvent, Restructure, and Reform’
-
REPharma Summit 2024: ‘Reinvent, Restructure, and Reform’
-
Indian Pharma Inc key drivers for 2024: Increased sustainability, energy-efficient practices, new technologies adoption
-
Pharma industry eyes sustained growth, more collaborative efforts in New Year
-
Indian Pharma poised to shape the next era of Global Health
-
Pharma sector to focus on supply chain, Covid mgmt
-
Indian pharma industry likely to grow to $130 bn by 2030
-
Panel for removing penal provisions from proposed Drugs Act for lapses
Advertisement
More in SUDARSHAN JAIN
-
-
Prolongation of coronavirus outbreak in China could hit Indian pharma sector
China accounted for 67.56 per cent of total imports of bulk drugs and drug intermediates in 2018-19 at USD 2,405.42 million.
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
